MedTrace Logo

The Biomarker Analysis in Locally Advanced Cervical Cancer

NCT03635216 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 62

Last updated 2018-08-17

No results posted yet for this study

Summary

Sonic hedgehog (Shh) signaling, including Gli1, is critical to treatment resistance. For optimizing cervical cancer treatment, the pathological prognostic factors determine whether to administer adjuvant therapy. However, the majority of clinical results was from squamous cell carcinoma, rendering conclusions for adenocarcinoma less convincing. We aimed to examine the role of Shh signaling in long-term clinical outcomes of cervical adenocarcinoma after receiving major surgery.

Conditions

  • Uterine Cervical Neoplasms

Sponsors & Collaborators

  • Mackay Memorial Hospital

    lead OTHER

Principal Investigators

  • Yu-Jen Chen, MD · Department of Radiation Oncology, MacKay Memorial Hospital

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-21
Primary Completion
2018-05-21
Completion
2023-05-20

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03635216 on ClinicalTrials.gov